A new commentary published in Diabetes, Obesity and Metabolism shares practical recommendations for gathering real world evidence on the use of GLP-1 medications in people with Prader-Willi syndrome
10.1210/jc.2009-1026 J
However, natural alternatives can be meaningful for those who don't qualify for prescriptions, can't tolerate medication side effects, or prefer a non-pharmaceutical approach
Recalls & Warnings September 09, 2011 Possible Concern with Fenugreek Based on Contamination in Europe Products made with fenugreek, including pills containing fenugreek seed, have been pulled from shelves in Germany due to conern over potential contamination with E
including semaglutide branded as Wegovy or Ozempic, and tirzepatide (dual GIP/GLP-1 receptor agonist) branded as Zepbound or Mounjaro, for the management of obesity, type 2 diabetes, and other metabolic conditions increases, so too does the need to assess the advantages and potential downsides of long-term use